Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,05,236 Cr
Revenue (TTM)
₹26,151 Cr
Net Profit (TTM)
₹4,645 Cr
ROE
21.1 %
ROCE
22 %
P/E Ratio
22.7
P/B Ratio
5.1
Industry P/E
29.25
EV/EBITDA
13.5
Div. Yield
0.5 %
Debt to Equity
0.3
Book Value
₹455.4
EPS
₹108.9
Face value
2
Shares outstanding
457,043,219
CFO
₹19,351.73 Cr
EBITDA
₹29,810.84 Cr
Net Profit
₹10,621.71 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lupin
| 9.1 | 2.4 | 9.0 | 15.6 | 51.9 | 17.7 | 3.2 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lupin
| -10.8 | 79.4 | 80.3 | -22.8 | -5.0 | 26.7 | -9.3 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lupin
|
2,302.4 | 1,05,236.5 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 |
| 26,375.0 | 55,882.2 | 6,824.1 | 1,524.1 | 25.9 | 37 | 36.7 | 12.7 | |
| 5,351.5 | 63,950.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,269.0 | 73,703.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.1 | 2.1 | |
| 382.6 | 61,967.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.6 | 1.6 | |
| 2,437.6 | 41,252.1 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.4 | 20.6 | |
| 1,543.6 | 39,123.7 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43 | 5.0 | |
| 2,103.1 | 86,793.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 48.8 | 5.5 | |
| 1,778.3 | 4,26,781.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 899.6 | 90,435.3 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.3 | 3.4 |
Stock Rating update, March 22, 2024
2 min read•By Value Research
Companies that went from hero to zero
3 min read•By Hemkesh Khattar
5 min read•By Research Desk
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars,... over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. Read more
Incorporated
1983
Chairman
Manju D Gupta
Managing Director
Nilesh Gupta
Group
Lupin
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Lupin Ltd is ₹2,302.40 (NSE) and ₹2,302.55 (BSE) as of 18-Mar-2026 IST. Lupin Ltd has given a return of 51.89% in the last 3 years.
The P/E ratio of Lupin Ltd is 22.66 times as on 18-Mar-2026, a 23 discount to its peers’ median range of 29.25 times.
The P/B ratio of Lupin Ltd is 5.06 times as on 18-Mar-2026, a 11 premium to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
28.20
|
5.40
|
|
2024
|
38.51
|
5.20
|
|
2023
|
68.54
|
2.39
|
|
2022
|
0.00
|
2.83
|
|
2021
|
38.08
|
3.40
|
The 52-week high and low of Lupin Ltd are Rs 2,377.60 and Rs 1,795.20 as of 19-Mar-2026.
Lupin Ltd has a market capitalisation of ₹ 1,05,236 Cr as on 18-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Lupin Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.20
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.